CLDX · Celldex Therapeutics Inc
United States · RS rating 21 · As of 2026-10-14
| Price | 27.83 USD |
|---|---|
| 1-day change | -1.5% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 7 / 18 / 50 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 25 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -20.8% |
| Sales growth Q/Q | -87.6% |
| Distance from 52-week high | +38.0% |
| Market cap (USD) | $2.6B |